Progenics Pharmaceuticals, Inc. Sustainability Profile
Progenics Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for cancer and other serious conditions. Founded in 1986, Progenics has made significant strides in the oncology sector, particularly with its pioneering work in radiopharmaceuticals and targeted therapies. The company is renowned for its flagship products, including the prostate cancer treatment, Azedra, which showcases Progenics' commitment to addressing unmet medical needs through unique therapeutic approaches. With a strong emphasis on research and development, Progenics has established a notable market position, recognised for its contributions to improving patient outcomes in oncology. As it continues to expand its portfolio, Progenics remains dedicated to advancing the field of cancer treatment and enhancing the quality of life for patients worldwide.
DitchCarbon Score
How does Progenics Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Progenics Pharmaceuticals, Inc.'s score of 25 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Progenics Pharmaceuticals, Inc.'s reported carbon emissions
Progenics Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. As a current subsidiary of Lantheus Holdings, Inc., any emissions data would be inherited from this parent company. However, there are no documented reduction targets or climate pledges from Progenics Pharmaceuticals, Inc. at this time. The absence of specific emissions figures and reduction initiatives highlights a potential area for improvement in their climate commitments. As the pharmaceutical industry increasingly focuses on sustainability, Progenics may benefit from establishing clear targets and strategies to reduce their carbon footprint in alignment with industry standards.
How Carbon Intensive is Progenics Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Progenics Pharmaceuticals, Inc.'s Location?
Progenics Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Progenics Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
